Francisco Sierra

Mr. Francisco Sierra

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2006 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
MBM. Isabel Baena
M. Isabel Baena
MFM. Jose Faus
M. Jose Faus
PFPaloma C. Fajardo
Paloma C. Fajardo
FLFrancisco M. Luque
Francisco M. Luque
FSFrancisco Sierra
Francisco Sierra
AZAntonio Zarzuelo
Antonio Zarzuelo

1 May 2017 in American Journal of Health-System Pharmacy
Verified
Journal Article
Closed access
PDF file
FFF. Dámaso Fernández-Ginés
F. Dámaso Fernández-Ginés
MCManuel Cortiñas-Sáenz
Manuel Cortiñas-Sáenz
HMHéctor Mateo-Carrasco
Héctor Mateo-Carrasco
AAAna Navajas-Gómez de Aranda
Ana Navajas-Gómez de Aranda
ENEstrella Navarro-Muñoz
Estrella Navarro-Muñoz
JMJosé Antonio Morales-Molina
José Antonio Morales-Molina
Purpose Results of efficacy and safety assessments of topical sevoflurane use in patients with long-term treatment-refractory vascular ulcers are reported. Methods Patients were randomly assigned to receive sevoflurane instillations (1 mL per cm2 of ulcer area 1–4 times daily) plus standard wound care (ulcer cleaning, debridement, and dressing changes) or standard care only. Topical sevoflurane was initiated during hospitalization, with self- or nurse-administered instillations continued after discharge. Study participants were evaluated at least once weekly for 1 month and then every 2 weeks for up to 90 days. The primary efficacy measures were debridement-related and overall pain (assessed using a 10-point visual analog scale), daily opioid use, and ulcer size; secondary measures were patient and clinician impressions of improvement and ulcer-related admissions during treatment. The primary safety endpoint was intolerable sevoflurane-related adverse effects. Results Compared with the group receiving standard care alone (n = 5), the sevoflurane group (n = 10) had significant (p = 0.001) reductions in mean ± S.D. scores for debridement-related pain on day 1 of treatment and at subsequent time points; the sevoflurane group also had significant reductions in overall pain, daily opioid use, and ulcer size. Outcomes in terms of patient- and clinician-rated improvement and emergency admissions also favored the sevoflurane group. Mild localized reddening in the area surrounding ulcers occurred in 4 sevoflurane-treated patients. Conclusion Direct application of sevoflurane onto vascular ulcers resulted in an intense and long-lasting analgesia and was associated with a progressive reduction of ulcer size.

25 November 2019 in International Wound Journal
Verified
Journal Article
Closed access
PDF file
FFF. Dámaso Fernández‐Ginés
F. Dámaso Fernández‐Ginés
MCManuel Cortiñas‐Sáenz
Manuel Cortiñas‐Sáenz
DADesirée Agudo‐Ponce
Desirée Agudo‐Ponce
AAAna Navajas‐Gómez de Aranda
Ana Navajas‐Gómez de Aranda
JMJosé A. Morales‐Molina
José A. Morales‐Molina
HMHéctor Mateo‐Carrasco
Héctor Mateo‐Carrasco

11 January 2018 in European Journal of Hospital Pharmacy
Verified
Journal Article
Open access
PDF file
FFF Dámaso Fernández-Ginés
F Dámaso Fernández-Ginés
MCManuel Cortiñas-Sáenz
Manuel Cortiñas-Sáenz
AAAna Navajas-Gómez de Aranda
Ana Navajas-Gómez de Aranda
MNMaria del Carmen Navas-Martinez
Maria del Carmen Navas-Martinez
JMJosé Antonio Morales-Molina
José Antonio Morales-Molina
HMHéctor Mateo-Carrasco
Héctor Mateo-Carrasco
A Caucasian 39-year-old male patient with a poorly-differentiated infiltrating epidermoid penile carcinoma with urethral invasion was diagnosed. The patient received concomitant adjuvant chemotherapy with radiotherapy in the palliative setting, which produced painful ulceration of tumour lesions at loco-regional level (Numerical Rate Scale, NRS=9). The patient consented for treatment with direct topical sevoflurane instillations, at initial doses of 1 mL/cm2 of ulcerated area, as per unit protocol. The local use of undiluted sevoflurane achieved a marked reduction of the pain score in both nociceptive and irruptive pains (average NRS=3 immediately post-application). This improvement was corroborated by a decline in total morphine needs, any adverse events associated with major opiates. PGI-I and CGI-I scales were used before and after treatment with topical sevoflurane to assess patient and clinician perceptions of improvement in the quality of life. The pharmacy of our hospital had the responsibility to elaborate pre-loaded syringes with sevoflurane so that the patient was instilled simply and comfortably.

9 January 2017 in International Wound Journal
Verified
Journal Article
Open access
FFF. Dámaso Fernández-Ginés
F. Dámaso Fernández-Ginés
MCManuel Cortiñas-Sáenz
Manuel Cortiñas-Sáenz
AAAna Navajas-Gómez De Aranda
Ana Navajas-Gómez De Aranda
RBRodrigo Yoldi Bocanegra
Rodrigo Yoldi Bocanegra
FSFrancisco Sierra
Francisco Sierra

1 July 2014 in Medicina Clinica
Verified
Journal Article
Closed access
EREmilio Jesús Alegre del Rey
Emilio Jesús Alegre del Rey
SCSilvia Fénix Caballero
Silvia Fénix Caballero
RLRocío Castaño Lara
Rocío Castaño Lara
FSFrancisco Sierra
Francisco Sierra